Introducing the first Psychopharmacology Committee Newsletter
Calling all members with an interest in psychopharmacology!
We’re excited to announce the launch of the first RCPsych Psychopharmacology Committee newsletter.
Sign up now (member login required) to receive it and learn about:
- why trainees should be interested in psychopharmacology
- prescribing wisely: using existing treatments better
- a lived experience prospective
- KarXT a new FDA-approved drug for schizophrenia
- and much more!
Our goal is to create an essential psychopharmacology resource for all psychiatrists, with relevant updates, insights, and learning opportunities, and to keep members informed on the latest Psychopharmacology hot topics and the activities from the committee.
Each issue, expected once a year, will feature a range of engaging topics, including:
- why psychopharmacology is vital for psychiatry trainees and sources of educational opportunities
- A 'Prescribing Wisely' section updating members on the latest treatment guidance
- Latest news from the Prescribing Observatory for Mental Health (POMH) and the Medicines and Healthcare products Regulatory Agency (MHRA)
- summaries of groundbreaking research findings
- lived experience perspectives
- other recent work from our Psychopharmacology Committee.
To stay connected to psychopharmacology from the RCPsych, subscribe to our newsletter to ensure you don’t miss an issue.
Read more
to receive further information regarding a career in psychiatry